TheraRadar
Data updated: May 26, 2026

CONDYLOX (podofilox)

Dermatology Approved 1990-12-13
2
Indications
--
Phase 3 Trials
1
Priority Reviews
35
Years on Market

Details

Status
Discontinued
First Approved
1990-12-13
Routes
TOPICAL
Dosage Forms
SOLUTION, GEL

Companies

Active Ingredient: PODOFILOX

CONDYLOX Approval History

1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
13 FDA actions from 1990 to 2015
Oct 2015 SUPPL Priority
Mfg · Manufacturing (CMC)
Sep 2015 SUPPL Priority
Mfg · Manufacturing (CMC)
Jan 2014 SUPPL Priority
Mfg · Manufacturing (CMC)

What CONDYLOX Treats

2 FDA approvals

Originally approved for its first indication in 1990 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CONDYLOX FDA Label Details

Track CONDYLOX with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.